Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

VIFOR PHARMA PORTUGAL, SA

NIF 516677586
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €2,329,061 39 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €2,329,061 39 contracts
A2 · Late Publication €7,706,009,719 530 contracts
Contract published to BASE more than 10 days after the signing date
LOW €7,706,009,719 530 contracts
A5 · Threshold Splitting €1,625,326 20 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €1,625,326 20 contracts
A6 · Low Competition €427,581 12 contracts
Only one bidder participated in a competitive procedure
MEDIUM €427,581 12 contracts
A9 · Abnormal Price Reduction €9,384,553,943 449 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €9,384,553,943 449 contracts
C3 · Missing Mandatory Fields €4,916,419 50 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €4,916,419 50 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

77
€718,122,634
20
€373,588,686
36
€359,681,612
33
€359,406,867
16
€350,868,764
20
€346,544,769
34
€343,424,403
13
€328,466,826
38
€322,474,759
18
€307,348,060
10
€307,102,444
21
€305,618,123
10
€303,245,798
9
€297,451,717
21
€297,014,080
16
€294,065,365
16
€292,477,138
9
€286,399,615
11
€253,828,092
8
€236,606,422
Page 1 of 3 · 53 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 20 contracts

Aquisição de Medicamentos Diversos - Adicionais 3
PT · 12020198 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€145,463 2025-12-03
61/444/2026 - Medicamento Avacopano 10 mg Cáps
PT · 13384571 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€145,896 2025-11-27
040123442025 SPARSENTANO 400 MG COMP
PT · 11909735 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +1
€19,980 2025-10-01
Aquisição de Medicamentos Exclusivos XVI
PT · 11559985 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€149,007 2025-07-02
VÁRIOS MEDICAMENTOS
PT · 11219229 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€73,545 2024-12-23
Aquisição de Medicamentos Diversos ao abrigo de vários Acordos Quadro, AQ 21/2020, 55/2021, 61/2021, 40/2022,55/2022, 173/2022 E 481/2023.
PT · 11237008 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting C3 · Missing Mandatory Fields
€19,277 2024-08-07
Aquisição de medicação antialérgica, vitaminas e sais minerais e medicamentos usados no tratamento de intoxicações
PT · 10786021 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€143,830 2024-05-15
BEAD20240023 - AQUISIÇÃO DE CORRECTIVOS DAS ALT. HIDROELECTROLÍTICAS - 1º SEMESTRE
PT · 10530656 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€19,068 2024-01-31
61/843/2024 - Medicamentos Patiromero
PT · 10681702 · Ajuste Direto Regime G...
A5 · Threshold Splitting A1 · Repeat Direct Award +2
€4,879 2024-01-03
AD_AQ n.º 51001523, ao abrigo do artigo 259.º do CCP - Aquisição de Medicamento ao Abrigo de Acordo Quadro 2023/304 (Medicamentos do Grupo 4: Sangue) - CARBOXIMALTOSE FÉRRICA [50 MG/ML; 10 ML; SOL INJ; F/AMP]
PT · 10391520 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€4,936 2023-10-12
Carboximaltose férrica 50 mg/ml Sol inj Fr 10 ml IV
PT · 11682872 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€4,936 2023-10-03
AQUISIÇÃO DE MEDICAMENTOS DO GRUPO 4: SANGUE AO ABRIGO DO ACORDO QUADRO 2020/018 DOS SPMS, EPE
PT · 9985790 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€143,453 2023-05-09
Medicamentos do grupo 4 (Sangue)
PT · 10247477 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€147,916 2023-05-03
ANTIEMÉTICOS E ANTIVERTIGINOSOSO - 1º SEMESTRE
PT · 9885071 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€71,509 2023-03-24
MEDICAMENTOS DIVERSOS
PT · 9947076 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,924 2023-03-15
DS_06/00053.11/2023 - Aquisição de medicamentos do Grupo 4 Sangue
PT · 9873442 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A9 · Abnormal Price Reduction
€147,428 2023-03-14
Q1/0550/2023 - Medicamentos Diversos
PT · 9813230 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€72,296 2023-02-10
Medicamentos do grupo 4: sangue ao abrigo do CPA n.º 2020/018
PT · 9985819 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€74,518 2023-01-08
MEDICAMENTOS CAPTADORES DE IOES - PATIRÓMERO
PT · 9443337 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€143,421 2022-09-02
Aquisição de CARBOXIMAL FERRICA IV 50MGML;10ML SOL I ao abrigo do CPA 2020/18 para o HFF para o ano 2022
PT · 9386043 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting
€74,043 2022-07-22
Overview
Total Value Won
€9,408,525,991
Contracts Won
811
Score 29580 · CRITICAL RISK
NIF
516677586
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.S. [P-b17a]
    Presidente
    since 2022-01-03
  • A.S. [P-b17a]
    Presidente
    since 2025-07-04
  • A.J. [P-1ffd]
    Vogal
    since 2023-08-10
  • A.J. [P-1ffd]
    Vogal
    since 2025-07-04
  • L.R. [P-b234]
    Vogal
    since 2025-07-04
  • D.A. [P-c2b1]
    Fiscal Único
    since 2024-08-12
  • D.A. [P-c2b1]
    Fiscal Único
    since 2025-07-04
  • J.C. [P-75e0]
    Fiscal Único
    since 2024-08-12
  • J.C. [P-75e0]
    Fiscal Único
    since 2025-07-04
  • A.B. [P-e78f]
    Vogal
    2022-04-11 → 2024-04-11
  • G.M. [P-e646]
    Vogal
    2022-01-03 → 2023-08-10
  • E.Y. [P-6b36]
    Fiscal Único
    2022-01-03 → 2024-08-12
  • L.M. [P-2cbf]
    Fiscal Único
    2022-01-03 → 2024-08-12
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned